Olema director Gorjan Hrustanovic resigns; Prakash Raman named to two board committees

Olema Pharmaceuticals, Inc.

Dr. Gorjan Hrustanovic notified Olema on October 12, 2026 of his resignation from the Board of Directors, effective October 14, 2026.
Hrustanovic also resigned from the Board's Compensation Committee and Science and Technology Committee; the filing states no disagreement with the company prompted the exit.
On October 15, 2026, the Board appointed Dr. Prakash Raman to the Compensation Committee and the Science and Technology Committee, effective the same day.
No permanent replacement for Hrustanovic's full board seat was disclosed in the filing; Sean Bohen, M.D., Ph.D., remains President and CEO.
Committee reshuffle only — no financial terms, equity awards or severance arrangements were described.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Gorjan Hrustanovic

Director

OLMA · Olema Pharmaceuticals, Inc.

Effective: 2026-10-14
Filed: October 15, 2026, 5:00 PM ET

On October 12, 2026, Dr. Gorjan Hrustanovic notified Olema Pharmaceuticals, Inc. (the “Company”) of his decision to resign from the Company’s Board of Directors (the “Board”), effective October 14, 2026. Dr. Hrustanovic also resigned from the Compensation Committee of the Board (the “Compensation Committee”) and the Science and Technology Committee of the Board (the “Science and Technology Committee”). Dr. Hrustanovic’s resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Gorjan Hrustanovic resigned as Director at Olema Pharmaceuticals, Inc..

Action: resigned
Role: Director

Exact text from the filing

On October 12, 2026, Dr. Gorjan Hrustanovic notified Olema Pharmaceuticals, Inc. (the “Company”) of his decision to resign from the Company’s Board of Directors (the “Board”), effective October 14, 2026. Dr. Hrustanovic also resigned from the Compensation Committee of the Board (the “Compensation Committee”) and the Science and Technology Committee of the Board (the “Science and Technology Committee”). Dr. Hrustanovic’s resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

View on SEC.gov

Olema Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-423002

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.